Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.
More biotech companies turn to private investors as the market churns volatile for life sciences. Here’s who’s scooping up the cash this week.
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.
The companies will design and develop targeted gene therapies for a liver-directed rare disease program and conduct additional studies for central nervous system-directed rare disease programs.
GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.
Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.
Proceeds will be used to assemble and develop a diversified pipeline of therapies to address sight-threatening illnesses.
Halberd has demonstrated it can control each of the top 10 antigens associated with various neurodegenerative diseases, including Alzheimer’s, Parkinson’s, epilepsy, TBI and PTSD.
Health authorities in Malawi discovered an outbreak of wild poliovirus type 1 on Thursday. The announcement comes after a case was detected in a young child in Lilongwe.
With IND approval, the therapeutics have become the first LBPs for Parkinson’s disease cleared by the FDA.
Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.
The COVID-19 pandemic and the virus that causes it, SARS-CoV-2, has been resilient, unpredictable and confounding from the very beginning.